ABVC BIOPHARMA, INC.

Listed Company

ABVCCIK 0001173313NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsNevadaFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-7.91M

Total Assets

$21.06M

Equity

$11.11M

Shares Out

26.00M

Op. Cash Flow

$-2.99M

ABVC$1.26−65.04% · past yearDBEQ Basic

Daily closing prices

Business

ABVC BioPharma is an early-stage biopharmaceutical company developing a pipeline of drug candidates and a medical device, all licensed from related parties, targeting central nervous system and oncology diseases. Its candidates include ABV-1504 for major depressive disorder, ABV-1505 for adult ADHD, and ABV-1701 as a vitreous substitute. The company owns a GMP manufacturing facility through subsidiary BioKey that produces drug products for clinical trials and dietary supplements. ABVC conducts clinical development in the United States, Taiwan, and Australia.

Summary from 10-K filed 2026-03-03

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	—	509,589	152,430	969,783	355,797
Cost of revenue	—	763	302,037	286,415	5,086
Gross profit	—	508,826	−149,607	683,368	350,711
Selling, general and administrative expenses	3	2	5	6	6
Research and development expenses	121,085	179,272	1	3	1
Stock-based compensation	4	3	185,933	7	5
Total operating expenses	7	5	7	16	12
Loss from operations	−7	−5	−7	−15	−12
Interest income	167,103	87,358	185,481	187,817	43,196
Interest expense	−415,890	−825,899	−1	—	—
Operating sublease income	134,196	48,478	65,900	—	—
Loss on foreign exchange changes	−77,546	−25,135	22,690	−259,463	426,316
Loss on investment in equity securities	−192,759	−339,171	−221,888	−7,446	—
Loss on impairment of equity investment	−803,008	—	—	—	—
Write off unclaimed accrued liabilities	—	255,592	—	—	—
Other (loss) income, net	−13,642	134,443	3,384	−24,149	495,141
Total other (expenses)	−1	−664,334	−1	−400,184	495,141
Loss before provision for income tax	−8	−5	−8	−16	−11
Provision for income tax expense (benefit)	24,154	−110,539	256,006	797,778	825,024
Net loss	−8	−5	−8	−16	−12
Net loss attributable to noncontrolling interests	−468,405	−356,159	−492,794	110,865	802,962
Net loss attributed to ABVC and subsidiaries	−8	−5	−8	−16	−13
Foreign currency translation adjustment	41,937	−70,722	−741	−22,532	−25,200
Comprehensive loss	−8	−5	−8	−16	−13
Basic (in Dollars per share)	−0.39	−0.42	−1.8	−5.19	−0.51
Diluted (in Dollars per share)	−0.39	−0.42	−1.8	−5.19	−0.51
Basic (in Shares)	20	12	4	3	25
Diluted (in Shares)	20	12	4	3	25

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	681,480	248,382	60,155	85,265	6
Restricted cash	645,505	615,433	656,625	—	—
Short-term investments	64,354	64,736	79,312	75,797	108,147
Prepaid expense and other current assets	346,616	96,213	101,051	150,235	528,354
Total Current Assets	3	2	2	3	8
Property and equipment, net	13	511,088	569,278	573,978	525,881
Operating lease right-of-use assets	2	640,387	809,283	1	1
Long-term investments	2	2	3	842,070	932,755
Prepayment for long-term investments	1	1	78,789	135,135	119,309
Prepayment for asset acquisition	691,900	691,900	691,900	—	—
Other non-current assets	116,966	133,121	141,231	—	—
Total Assets	21	8	8	10	14
Short-term bank and other loans	755,512	840,252	899,250	2	—
Accrued expenses and other current liabilities	4	4	4	—	—
Contract liabilities	12,600	81,115	79,500	10,985	—
Operating lease liabilities current	317,557	403,581	401,826	369,314	347,100
Tax payable	11,964	—	112,946	—	—
Convertible notes payable third parties, net	559,010	950,046	—	—	—
Total Current Liabilities	6	7	6	6	4
Tenant security deposit	—	21,680	21,680	7,980	10,580
Operating lease liability non-current	2	236,807	407,457	791,827	1
Total Liabilities	8	7	7	6	5
COMMITMENTS AND CONTINGENCIES	—	—	—	—	—
Preferred stock, $0.001 par value, 20,000,000 authorized, nil shares issued and outstanding	—	—	—	—	—
Common stock, $0.001 par value, 100,000,000 authorized, 25,053,193 and 13,868,484 shares issued and outstanding as of December 31, 2025 and 2024, respectively	25,053	13,868	7,940	3,286	28,926
Stock to be issued	359,000	31,040	—	—	—
Additional paid-in capital	96	79	74	68	58
Accumulated deficit	−77	−69	−64	−55	−38
Accumulated other comprehensive income	487,602	445,665	516,387	517,128	539,660
Treasury stock	−9	−9	−9	−9	−9
Total Stockholders equity	11	1	2	3	9
Noncontrolling interest	2	−502,181	−300,637	137,554	26,689
Total Equity	13	723,959	1	3	9
Total Liabilities and Equity	21	8	8	10	14

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation	25,330	32,025	28,531	23,799	11,993
Inventory write-down	11,460	—	—	—	—
Provision for doubtful accounts	—	11,993	1	184,589	—
Other non-cash expenses, net	351,085	532,769	—	—	—
Amortization of right-of-use asset	479,504	168,896	351,859	—	—
Inventory	−11,460	—	—	—	−25,830
Prepaid expenses and other current assets	−71,653	12,948	101,926	238,092	—
Due from related parties	−136,501	−293,962	−321,776	−837,014	−595,037
Accrued expenses and other current liabilities	152,207	152,819	638,762	2	−173,151
Contract liabilities	−68,515	1,615	68,515	—	—
Tenant security deposit	−16,865	—	13,700	−2,600	−357,276
Taxes payables	11,964	−112,946	112,946	—	—
Operating lease liabilities	−474,479	−168,896	−351,859	—	—
Net cash used in operating activities	−3	−2	−4	−7	−8
Loan to related parties	−1	—	—	—	—
Repayment from related parties	203,026	—	—	—	—
Transaction costs for acquiring land	−5,794	—	—	—	—
Net cash used in investing activities	−1	—	−360,186	−2	−805,966
Proceeds from private placement	3	—	—	—	—
Proceeds from exercise of warrants	991,366	947,500	—	—	—
Proceeds from convertible notes payable third parties	499,010	342,095	1	—	—
Repayment of convertible notes payable third parties	−277,284	−327,017	—	—	−306,836
Proceeds from convertible notes payable related parties	390,000	—	—	—	—
Repayment of convertible notes payable related parties	−150,000	—	—	—	—
Repayment of short-term bank loans	−120,400	−29,152	−1	—	—
Proceeds from related party payables	—	599,552	—	—	—
Proceeds from issuance of warrants	—	394,071	2	—	—
Repurchase of treasury stocks	—	−7,320	—	—	—
Proceeds from issuance of a promissory note	—	30,000	—	350,000	—
Proceeds from common stock subscription	—	31,040	—	—	—
Net cash provided by financing activities	5	2	4	4	10
Effect of exchange rate changes on cash and cash equivalents and restricted cash	20,264	−24,589	2,125	−67,337	−28,021
Net increase in cash and cash equivalents and restricted cash	463,170	147,035	−674,948	−5	2
Interest expense paid	31,518	22,539	33,180	285,465	333,873
Income taxes paid	12,077	25,863	27,392	—	—
Issuance of subsidiarys commons stock to acquire the control of the land	8	—	3	—	—
Issuance of common stock and stock warrants in the land acquisition	4	—	—	—	—
Increase in ROU asset and lease liabilities due to lease amendment	2	—	—	—	—
Conversion of convertible note due from related parties to equity investment	563,819	—	—	—	3
Assuming loan in the land acquisition	500,000	—	—	—	—
Issuance of common stock for conversion of debt	463,847	593,714	—	—	—
Issuance of subsidiarys common stock for consulting services	—	383,500	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is ABVC BIOPHARMA, INC.'s CIK number?

ABVC BIOPHARMA, INC.'s SEC CIK number is 0001173313 (1173313). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find ABVC BIOPHARMA, INC.'s SEC filings?

All of ABVC BIOPHARMA, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did ABVC BIOPHARMA, INC. last report earnings?

ABVC BIOPHARMA, INC. (ABVC) most recently filed an earnings 8-K with the SEC on Mar 3, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001213900-26-023054). This is ABVC BIOPHARMA, INC.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is ABVC BIOPHARMA, INC.'s most recent earnings 8-K?

ABVC BIOPHARMA, INC.'s latest earnings 8-K (Item 2.02) was filed Mar 3, 2026 under accession 0001213900-26-023054. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View ABVC BIOPHARMA, INC.'s latest earnings 8-K →
Look up any company's CIK number →